Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Weiva Sieh is active.

Publication


Featured researches published by Weiva Sieh.


Cancer Causes & Control | 2006

Genetic Susceptibility to Prostate Cancer: Prostate-specific Antigen and its Interaction with the Androgen Receptor (United States)

Weiva Sieh; Karen L. Edwards; Annette L. Fitzpatrick; Sengkeo L. Srinouanprachanh; Fred M. Farin; Stephanie A. Monks; Richard A. Kronmal; David L. Eaton

Objective To determine whether directly observed prostate-specific antigen (PSA) promoter diploid haplotype, either alone or in conjunction with androgen receptor (AR) genotype, is associated with prostate cancer risk.Methods We conducted a case–control study nested within the US population-based Cardiovascular Health Study cohort. Incident prostate cancers were identified by linkage to cancer registry records for the years 1989–2000. We genotyped 193 cases and 391 controls for the PSA −252 G/A and −158 G/A SNPs and the AR CAG microsatellite, and developed methods to directly determine proximal PSA promoter haplotypes. Exact logistic regression was used to estimate odds ratios and significance levels.Results No significant associations were observed between PSA diplotype and prostate cancer overall. Short (<20) AR CAG repeat lengths were associated with modest increases in the risk of prostate cancer (OR, 1.46; 95% CI, 0.97–2.19; p = 0.071) that were significant for advanced disease (OR, 1.82; 95% CI, 1.02–3.26; p = 0.044). Men who possessed two copies of the PSA*2 (−252G/−158G) haplotype and short AR CAG repeat lengths had a 4-fold (95% CI, 1.05–20.75; exact p = 0.040) increased risk of prostate cancer, and a 7-fold (95% CI, 1.25–39.78; exact p = 0.026) increased risk of advanced disease.Conclusions We found evidence that the PSA*2*2 diplotype in combination with short AR CAG alleles increases a man’s risk of developing prostate cancer. These findings support an etiologic role in prostate cancer of genetic interactions between polymorphisms that increase AR transactivation strength and those that alter the regulatory regions of target genes such as PSA that are responsive to androgen stimulation.


BMC Genetics | 2005

Comparison of marker types and map assumptions using Markov chain Monte Carlo-based linkage analysis of COGA data

Weiva Sieh; Saonli Basu; Audrey Qiuyan Fu; Joseph H. Rothstein; Paul Scheet; William Stewart; Yun J. Sung; E. A. Thompson; Ellen M. Wijsman

We performed multipoint linkage analysis of the electrophysiological trait ECB21 on chromosome 4 in the full pedigrees provided by the Collaborative Study on the Genetics of Alcoholism (COGA). Three Markov chain Monte Carlo (MCMC)-based approaches were applied to the provided and re-estimated genetic maps and to five different marker panels consisting of microsatellite (STRP) and/or SNP markers at various densities. We found evidence of linkage near the GABRB1 STRP using all methods, maps, and marker panels. Difficulties encountered with SNP panels included convergence problems and demanding computations.


JAMA Oncology | 2017

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ellen L. Goode; Matthew S. Block; Kimberly R. Kalli; Robert A. Vierkant; Wenqian Chen; Zachary C. Fogarty; Aleksandra Gentry-Maharaj; Aleksandra Tołoczko; Alexander Hein; Aliecia L. Bouligny; Allan Jensen; Ana Osorio; Andreas D. Hartkopf; Andy Ryan; Anita Chudecka-Głaz; Anthony M. Magliocco; Arndt Hartmann; Audrey Y. Jung; Bo Gao; Brenda Y. Hernandez; Brooke L. Fridley; Bryan M. McCauley; Catherine J. Kennedy; Chen Wang; Chloe Karpinskyj; Christiani Bisinoto de Sousa; Daniel Guimarães Tiezzi; David L. Wachter; Esther Herpel; Florin Andrei Taran

Importance Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. Objective To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. Design, Setting, and Participants This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. Exposures Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. Main Outcomes and Measures Overall survival time. Results The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. Conclusions and Relevance This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.


Human Heredity | 2007

Accounting for Linkage Disequilibrium among Markers in Linkage Analysis: Impact of Haplotype Frequency Estimation and Molecular Haplotypes for a Gene in a Candidate Region for Alzheimer’s Disease

Weiva Sieh; Chang En Yu; Bird Td; Gerard D. Schellenberg; Ellen M. Wijsman

Objectives: Linkage disequilibrium (LD) between closely spaced SNPs can be accommodated in linkage analysis by specifying the multi-SNP haplotype frequencies, if known. Phased haplotypes in candidate regions can provide gold standard haplotype frequency estimates, and may be of inherent interest as markers. We evaluated the effects of different methods of haplotype frequency estimation, and the use of marker phase information, on linkage analysis of a multi-SNP cluster in a candidate region for Alzheimer’s disease (AD). Methods: We performed parametric linkage analysis of a five-SNP cluster in extended pedigrees to compare the use of: (1) haplotype frequencies estimated by molecular phase determination, maximum likelihood estimation, or by assuming linkage equilibrium (LE); (2) AD families or controls as the frequency source; and (3) unphased or molecularly phased SNP data. Results: There was moderate to strong pairwise LD among the five SNPs. Falsely assuming LE substantially inflated the LOD score, but the method of haplotype frequency estimation and particular sample used made little difference provided that LD was accommodated. Use of phased haplotypes produced a modest increase in the LOD score over unphased SNPs. Conclusions: Ignoring LD between markers can lead to substantially inflated evidence for linkage in LOD score analysis of extended pedigrees with missing data. Use of marker phase information in linkage analysis may be important in disease studies where the costs of family recruitment and phenotyping greatly exceed the costs of phase determination.


International Journal of Cancer | 2017

Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 19 studies

Camilla Præstegaard; Allan Jensen; Signe M. Jensen; Thor Schütt Svane Nielsen; Penelope M. Webb; Christina M. Nagle; Anna deFazio; Estrid Høgdall; Mary Anne Rossing; Jennifer A. Doherty; Kristine G. Wicklund; Marc T. Goodman; Francesmary Modugno; Kirsten B. Moysich; Roberta B. Ness; Robert P. Edwards; Keitaro Matsuo; Satoyo Hosono; Ellen L. Goode; Stacey J. Winham; Brooke L. Fridley; Daniel W. Cramer; Kathryn L. Terry; Joellen M. Schildkraut; Andrew Berchuck; Elisa V. Bandera; Lisa E. Paddock; Leon F.A.G. Massuger; Nicolas Wentzensen; Paul Pharoah

Cigarette smoking is associated with an increased risk of developing mucinous ovarian tumors but whether it is associated with ovarian cancer survival overall or for the different histotypes is unestablished. Furthermore, it is unknown whether the association between cigarette smoking and survival differs according to strata of ovarian cancer stage at diagnosis. In a large pooled analysis, we evaluated the association between various measures of cigarette smoking and survival among women with epithelial ovarian cancer. We obtained data from 19 case‐control studies in the Ovarian Cancer Association Consortium (OCAC), including 9,114 women diagnosed with ovarian cancer. Cox regression models were used to estimate adjusted study‐specific hazard ratios (HRs), which were combined into pooled hazard ratios (pHR) with corresponding 95% confidence intervals (CIs) under random effects models. Overall, 5,149 (57%) women died during a median follow‐up period of 7.0 years. Among women diagnosed with ovarian cancer, both current (pHR = 1.17, 95% CI: 1.08–1.28) and former smokers (pHR = 1.10, 95% CI: 1.02–1.18) had worse survival compared with never smoking women. In histotype‐stratified analyses, associations were observed for mucinous (current smoking: pHR = 1.91, 95% CI: 1.01–3.65) and serous histotypes (current smoking: pHR = 1.11, 95% CI: 1.00–1.23; former smoking: pHR = 1.12, 95% CI: 1.04–1.20). Further, our results suggested that current smoking has a greater impact on survival among women with localized than disseminated disease. The identification of cigarette smoking as a modifiable factor associated with survival has potential clinical importance as a focus area to improve ovarian cancer prognosis.


International Journal of Epidemiology | 2018

Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies

Lauren C. Peres; Harvey A. Risch; Kathryn L. Terry; Penelope M. Webb; Marc T. Goodman; Anna H. Wu; Anthony J. Alberg; Elisa V. Bandera; Jill S. Barnholtz-Sloan; Melissa L. Bondy; Michele L. Cote; Ellen Funkhouser; Patricia G. Moorman; Edward S. Peters; Ann G. Schwartz; Paul Terry; Ani Manichaikul; Sarah E. Abbott; Fabian Camacho; Susan J. Jordan; Christina M. Nagle; Mary Anne Rossing; Jennifer A. Doherty; Francesmary Modugno; Kirsten B. Moysich; Roberta B. Ness; Andrew Berchuck; Linda S. Cook; Nhu D. Le; Angela Brooks-Wilson

Background Ovarian cancer incidence differs substantially by race/ethnicity, but the reasons for this are not well understood. Data were pooled from the African American Cancer Epidemiology Study (AACES) and 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC) to examine racial/ethnic differences in epidemiological characteristics with suspected involvement in epithelial ovarian cancer (EOC) aetiology. Methods We used multivariable logistic regression to estimate associations for 17 reproductive, hormonal and lifestyle characteristics and EOC risk by race/ethnicity among 10 924 women with invasive EOC (8918 Non-Hispanic Whites, 433 Hispanics, 911 Blacks, 662 Asian/Pacific Islanders) and 16 150 controls (13 619 Non-Hispanic Whites, 533 Hispanics, 1233 Blacks, 765 Asian/Pacific Islanders). Likelihood ratio tests were used to evaluate heterogeneity in the risk factor associations by race/ethnicity. Results We observed statistically significant racial/ethnic heterogeneity for hysterectomy and EOC risk (P = 0.008), where the largest odds ratio (OR) was observed in Black women [OR = 1.64, 95% confidence interval (CI) = 1.34-2.02] compared with other racial/ethnic groups. Although not statistically significant, the associations for parity, first-degree family history of ovarian or breast cancer, and endometriosis varied by race/ethnicity. Asian/Pacific Islanders had the greatest magnitude of association for parity (≥3 births: OR = 0.38, 95% CI = 0.28-0.54), and Black women had the largest ORs for family history (OR = 1.77, 95% CI = 1.42-2.21) and endometriosis (OR = 2.42, 95% CI = 1.65-3.55). Conclusions Although racial/ethnic heterogeneity was observed for hysterectomy, our findings support the validity of EOC risk factors across all racial/ethnic groups, and further suggest that any racial/ethnic population with a higher prevalence of a modifiable risk factor should be targeted to disseminate information about prevention.


Cancer Epidemiology, Biomarkers & Prevention | 2017

No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival

Lara E. Sucheston-Campbell; Rikki Cannioto; Alyssa Clay; John Lewis Etter; Kevin H. Eng; Song Liu; Sebastiano Battaglia; Qiang Hu; J. Brian Szender; Albina N. Minlikeeva; Janine M. Joseph; P.C. Mayor; Scott I. Abrams; Brahm H. Segal; Paul K. Wallace; Kah Teong Soh; Emese Zsiros; Hoda Anton-Culver; Elisa V. Bandera; Matthias W. Beckmann; Andrew Berchuck; Line Bjørge; Amanda S. Bruegl; Ian G. Campbell; Shawn Patrice Campbell; Georgia Chenevix-Trench; Daniel W. Cramer; Agnieszka Dansonka-Mieszkowska; Fanny Dao; Brenda Diergaarde

Background: The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/protumorigenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses. Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive EOC. Versatile Gene-based Association Study and the admixture likelihood method were used to test gene and pathway associations with survival. Results: We did not identify individual SNPs that were significantly associated with survival after correction for multiple testing (P < 3.5 × 10−5), nor did we identify significant associations between the MDSC pathway overall, or the 24 individual genes and EOC survival. Conclusions: In this well-powered analysis, we observed no evidence that inherited variations in MDSC-associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes. Impact: Common inherited variation in genes relevant to MDSCs was not associated with survival in women diagnosed with invasive EOC. Cancer Epidemiol Biomarkers Prev; 26(3); 420–4. ©2016 AACR.


Bioinformatics | 2017

FIRE: functional inference of genetic variants that regulate gene expression

Nilah M. Ioannidis; Joe R. Davis; Marianne K. DeGorter; Nicholas B. Larson; Shannon K. McDonnell; Amy J. French; Alexis Battle; Trevor Hastie; Stephen N. Thibodeau; Stephen B. Montgomery; Carlos Bustamante; Weiva Sieh; Alice S. Whittemore

Motivation: Interpreting genetic variation in noncoding regions of the genome is an important challenge for personal genome analysis. One mechanism by which noncoding single nucleotide variants (SNVs) influence downstream phenotypes is through the regulation of gene expression. Methods to predict whether or not individual SNVs are likely to regulate gene expression would aid interpretation of variants of unknown significance identified in whole‐genome sequencing studies. Results: We developed FIRE (Functional Inference of Regulators of Expression), a tool to score both noncoding and coding SNVs based on their potential to regulate the expression levels of nearby genes. FIRE consists of 23 random forests trained to recognize SNVs in cis‐expression quantitative trait loci (cis‐eQTLs) using a set of 92 genomic annotations as predictive features. FIRE scores discriminate cis‐eQTL SNVs from non‐eQTL SNVs in the training set with a cross‐validated area under the receiver operating characteristic curve (AUC) of 0.807, and discriminate cis‐eQTL SNVs shared across six populations of different ancestry from non‐eQTL SNVs with an AUC of 0.939. FIRE scores are also predictive of cis‐eQTL SNVs across a variety of tissue types. Availability and implementation: FIRE scores for genome‐wide SNVs in hg19/GRCh37 are available for download at https://sites.google.com/site/fireregulatoryvariation/. Contact: [email protected] Supplementary information: Supplementary data are available at Bioinformatics online.


The Journal of Pathology: Clinical Research | 2018

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Peter F. Rambau; Robert A. Vierkant; Maria P. Intermaggio; Linda E. Kelemen; Marc T. Goodman; Esther Herpel; Paul Pharoah; Stefan Kommoss; Mercedes Jimenez-Linan; Beth Y. Karlan; A Gentry-Maharaj; Usha Menon; S Hernando Polo; F.J Candido dos Reis; Ja Doherty; Simon A. Gayther; Raghwa Sharma; Melissa C. Larson; Paul Harnett; E Hatfield; Jm de Andrade; Gregg Nelson; Helen Steed; Joellen M. Schildkraut; Michael E. Carney; Estrid Høgdall; Alice S. Whittemore; Martin Widschwendter; Catherine J. Kennedy; F Wang

We aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical‐grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis‐associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while absence was associated with shorter OS in low‐grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype‐specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low‐grade serous carcinoma justifies CDK4 inhibition.


BMC Proceedings | 2007

Comparison of multipoint linkage analyses for quantitative traits in the CEPH data: parametric LOD scores, variance components LOD scores, and Bayes factors

Yun Ju Sung; Yanming Di; Audrey Qiuyan Fu; Joseph H. Rothstein; Weiva Sieh; Liping Tong; E. A. Thompson; Ellen M. Wijsman

Collaboration


Dive into the Weiva Sieh's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marc T. Goodman

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brooke L. Fridley

University of South Florida

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francesmary Modugno

University of Texas Health Science Center at Houston

View shared research outputs
Researchain Logo
Decentralizing Knowledge